Serum neutralization of SARS‐CoV‐2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant is undergoing continuous evolution and convergent mutation. These new subvariants are raising concerns that they may evade neutralizing monoclonal antibodies (mAbs). We investigated the serum neutralization efficacy of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical virology 2023-07, Vol.95 (7), p.e28932-n/a
Hauptverfasser:	Zhao, Qianqian, Wang, Xin, Zhang, Ze, Liu, Xuefei, Wang, Ping, Cao, Jin, Liang, Qiming, Qu, Jieming, Zhou, Min
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Neutralizing Antibodies, Viral China Coronaviruses COVID-19 Humans Monoclonal antibodies Neutralization Neutralizing receptor‐binding domain Respiratory diseases SARS-CoV-2 - genetics SARS‐CoV‐2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 variants Viral diseases Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!